TheraCryf (LSE:TCF) has announced encouraging topline toxicology findings for its lead Orexin-1 receptor blocker under development for addiction treatment. Initial dosing studies in the first animal species demonstrated the candidate was well tolerated at exposure levels up to 100 times higher than the projected therapeutic dose for humans.
The biotechnology group also reported significant progress in manufacturing, successfully scaling production to more than 2kg of clinical-grade material. In addition, the company has submitted a manufacturing-related patent application that could provide intellectual property protection through to 2046.
TheraCryf said its clinical trial-enabling programme continues to move ahead of schedule, with the remaining preclinical activities expected to conclude by the end of the third quarter of 2026. The company is targeting submission of a Phase 1 clinical trial application later that year.
Management highlighted the strategic importance of reaching Phase 1 development, describing it as a key valuation milestone in the global substance use disorder market, estimated to exceed $70bn. The company also pointed to continued deal activity across the neuroscience sector and revealed it had already rejected at least one approach that it believed undervalued the business, while discussions with additional potential partners remain ongoing.
Despite the operational momentum, the company’s investment case continues to be weighed down by weak financial metrics, including ongoing losses and cash outflows, even though the balance sheet remains free of debt. Market technical indicators remain broadly constructive due to share price performance relative to moving averages, although an elevated RSI suggests the stock may face short-term pressure after becoming overbought. Valuation metrics are also limited by the absence of profitability and dividend support.
More about TheraCryf plc
TheraCryf plc is a UK biotechnology company focused on developing therapies targeting addiction and other central nervous system disorders. Its primary programme centres on a novel Orexin-1 receptor antagonist aimed at treating conditions such as binge eating disorder, alcohol dependence, and substance abuse. The company is also advancing earlier-stage research programmes focused on fatigue linked to brain disorders and glioblastoma.
Leave a Reply